Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.58 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL214641 | 1.00 | FOLH1 (0.58) | FOLH1SLC6A5GSRRNPEPSIRT6 | |
| Hydrochloric Acid SCHEMBL2166126 | 0.98 | FOLH1 (0.57) | FOLH1SLC6A5GSRRNPEPSIRT6 | |
| Hydrochloric Acid SCHEMBL15914484 | 0.98 | FOLH1 (0.57) | FOLH1SLC6A5GSRRNPEPSIRT6 | |
| Acetic Acid SCHEMBL268740 | 0.98 | FOLH1 (0.57) | FOLH1SLC6A5GSRRNPEPSIRT6 | |
| SCHEMBL867577 | 0.95 | FOLH1 (0.51) | FOLH1SLC6A5GSRRNPEPSIRT6 | |
| SCHEMBL866580 | 0.95 | FOLH1 (0.51) | FOLH1SLC6A5GSRRNPEPSIRT6 | |
| SCHEMBL232125 | 0.95 | FOLH1 (0.51) | FOLH1SLC6A5GSRRNPEPSIRT6 | |
| Hydrochloric Acid SCHEMBL1982438 | 0.93 | FOLH1 (0.50) | FOLH1SLC6A5GSRSIRT6SIRT1 | |
| Hydrochloric Acid SCHEMBL1982441 | 0.93 | FOLH1 (0.50) | FOLH1SLC6A5GSRSIRT6SIRT1 | |
| SCHEMBL919220 | 0.85 | FOLH1 (0.62) | FOLH1SLC6A5GSRRNPEPSIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103127147-A | Medicine composition containing budesonide and nitric oxide synthase (NOS) inhibitor and for treating nose inflammation | TIANJIN JINYAO GROUP CO LTD | 2013-06-05 | — | — | CN | claimed |
| CN-103127132-A | Dermal medicine composition containing fluticasone propionate and nitric oxide synthase (NOS) inhibitor | TIANJIN JINYAO GROUP CO LTD | 2013-06-05 | — | — | CN | claimed |
| CN-103127141-A | Inhalation drug composition with mometasone furoate and nitric oxide synthase (NOS) inhibitor | TIANJIN JINYAO GROUP CO LTD | 2013-06-05 | — | — | CN | claimed |
| CN-102949400-A | Medicinal composition containing glucocorticoid and NOS (Nitric Oxide Synthase) inhibitor for treating nasal inflammation | TIANJIN JINYAO GROUP CO LTD | 2013-03-06 | — | — | CN | claimed |
| CN-102949723-A | Medicinal composition containing glucocorticoid and NOS (Nitric Oxide Synthase) inhibitor for treating skin inflammation | TIANJIN JINYAO GROUP CO LTD | 2013-03-06 | — | — | CN | claimed |
| CN-102949721-A | Transdermal absorption pharmaceutical composition containing testosterone and NOS inhibitor | TIANJIN JINYAO GROUP CO LTD | 2013-03-06 | — | — | CN | claimed |
| CN-102949724-A | Inhalation medicine composition containing glucocorticoid and NOS (nitric oxide synthase) inhibitor | TIANJIN JINYAO GROUP CO LTD | 2013-03-06 | — | — | CN | claimed |
| US-20100221247-A1 | AGENTS AND METHODS FOR TREATMENT OF CANCER | BENDER ROBERT | 2010-09-02 | — | — | US | claimed |
| US-20090326017-A1 | PAIN-RELIEVING COMPOSITIONS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2009-12-31 | — | — | US | claimed |
| US-20090298747-A1 | Methods and Compositions For Treatment of Nitric Oxide-Induced Clinical Conditions | BIO HOLDING, INC. (US) | 2009-12-03 | — | — | US | claimed |
| WO-2008080194-A1 | PAIN-RELIEVING COMPOSITIONS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2008-07-10 | — | — | WO | claimed |
| EP-1502604-A1 | Use of nitric oxide mimetics in cancer treatment | Cellegy Pharmaceuticals, Inc (US) | 2005-02-02 | — | — | EP | claimed |
| EP-1492567-A1 | FORMULATIONS AND METHODS OF USING NITRIC OXIDE MIMETICS IN CANCER TREATMENT | Cellegy Pharmaceuticals, Inc (US) | 2005-01-05 | — | — | EP | claimed |
| EP-1278547-B1 | FORMULATIONS AND METHODS OF USING NITRIC OXIDE MIMETICS AGAINST A MALIGNANT CELL PHENOTYPE | CELLEGY PHARMA INC (US) | 2004-11-03 | — | — | EP | claimed |
| US-20030215528-A1 | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype | QUEENS UNIVERSITY AT KINGSTON (CA) | 2003-11-20 | — | — | US | claimed |
| WO-2003074082-A1 | FORMULATIONS AND METHODS OF USING NITRIC OXIDE MIMETICS IN CANCER TREATMENT | CELLEGY PHARMACEUTICALS, INC. (CA) | 2003-09-12 | — | — | WO | claimed |
| US-6586478-B2 | Administering nitrogen oxide mimetic | CELLEGY CANADA (CA) | 2003-07-01 | — | — | US | claimed |
| US-5756451-A | ANTIISCHEMIC AGENTS | COR THERAPEUTICS, INC. (US) | 1998-05-26 | — | — | US | claimed |
| EP-0618898-A1 | AMIDINO DERIVATIVES AND THEIR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-10-12 | — | — | EP | claimed |
| WO-1993013055-A1 | AMIDINO DERIVATIVES AND THEIR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-07-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326017-A1 | PAIN-RELIEVING COMPOSITIONS AND USES THEREFOR | NOS2, NOS1, NOS3 | FOLH1 2749/4885SLC6A5 750/4885GSR 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.